Interestingly, the combination of CTX plus the PKI-587 (PI3K/mTOR inhibitor), namely Gedatolisib, which restored sensitivity to CTX in resistant HNSCC cell lines and xenografts (124), is found to have a greater synergistic enhancement of the CTX effectiveness, especially in basal-like HNSCC cells with mutated CDKN2A (118). Here, CDKN2A is linked to head and neck squamous cell carcinoma.